Elinzanetant

Bayer and Detroit-based Henry Ford Health announced a clinical trials partnership designed to connect more patients with investigational medicines, positioning Henry Ford as one of just four US academic health systems selected for Bayer’s strategic research network. The tie-up spans cardiovascular and renal disease, oncology and women’s health — three areas central to Bayer’s current pipeline — and reflects a broader industry shift toward embedding drug developers directly within health systems that serve large, diverse patient populations. Financial terms were not disclosed, and no specific drug candidate, technology platform or clinical trial identifier was named in the announcement. Under the agreement, Bayer will combine its clinical development capabilities with Henry Ford Health’s trial infrastructure, electronic health record data and patient population to improve trial design, identify eligible participants and generate real-world evidence. The companies also plan to collaborate on data science training. No specific investigational therapies or clinical studies were disclosed. The Henry Ford agreement is the second of its kind for Bayer within two weeks. On July 7, Bayer formed its first-ever academic medical center alliance with the University of Colorado Anschutz, UCHealth and Children’s Hospital Colorado, covering a similar mix of therapeutic areas along with neurodegenerative disease and cell and gene therapy. That deal marked Bayer’s first structured academic health system research network, and the Henry Ford partnership confirms the company is now executing a repeatable model rather than a one-off collaboration. With two of four planned network partners now named, Bayer appears to be assembling a distributed clinical trial infrastructure that spans multiple US regions and patient populations, though the identities of the remaining two systems have not been disclosed. The timing aligns with Bayer’s broader pharmaceutical strategy update from January, in which the company detailed a modality-rich pipeline spanning oncology assets such as darolutamide (Nubeqa) and sevabertinib (Hyrnuo), cardiovascular programs including asundexian and finerenone (Kerendia), and women’s health therapy elinzanetant (Lynkuet). Embedding clinical trial access within large health systems supports patient enrollment for this expanding portfolio, particularly as Bayer pushes multiple Phase III cardiovascular and oncology programs toward regulatory milestones in the coming years. For Henry Ford Health, the Bayer partnership adds to a growing list of external collaborations tied to its research and data capabilities, including its earlier work with BD on pharmacy automation and its role within the Truveta real-world data consortium. The health system’s chief scientific officer, David Lanfear, framed the Bayer collaboration as an effort to reduce participation barriers and accelerate treatment development, while Bayer’s Christoph Koenen pointed to community-embedded research as a way to reach patients where they already receive care. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team. Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Bayer secures profits lost through expired exclusivities with expanded indications in the US, but admits the strategy may not work for future patent cliffs. Credit: brunocoelho/Shutterstock.com Bayer is re-entering key assets in the US market under new indications to reclaim lost profits from patent expirations for its flagship therapies, a move it notes cannot be relied upon to face future exclusivity losses. At the J.P. Morgan Healthcare Conference 2026, taking place in San Francisco from 12 to 15 January, company’s head of pharmaceuticals, Stefan Oelrich, described its satisfaction with expanded indications in the US for Nubeqa (darolutamide) and Kerendia (finerenone) to plug a growing gap in profits left by the exclusivity expiries of Xarelto (rivaroxaban) and Eylea (aflibercept). However, Oelrich said relaunches of marketed assets may not sustain Bayer through a future patent cliff and that the company has therefore placed significant focus on its early-stage pipeline. Bayer lost its US patent on Xarelto, its factor Xa inhibitor, in 2025, which alone accounted for an estimated €1bn–€1.5bn of lost 2025 revenues, Oelrich said. The company is set to lose its patent on Eylea in 2027. Though these losses are expected to negatively impact revenues in the next few years, Oelrich said the company is relying on five assets to drive growth and reclaim near-term profits. These include continued EU (European Union) launches in 2026 of Beyonttra (acoramidis) for transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM), for which Bayer acquired the EU and UK rights from BridgeBio in March 2024 for $130m. Oelrich also pointed to Lynkuet (elinzanetant) for menopause management, gained through the acquisition of KaNDY in September 2020 for $425m, as well as oral anticoagulant asundexian for which Bayer hopes to gain approval in secondary stroke by the end of 2026. Crucially, Oelrich said indication expansions for Nubeqa and Kerendia had buttressed Bayer’s revenues against patent losses. In June 2025, Nubeqa secured fresh US Food and Drug Administration (FDA) approval for advanced prostate cancer, while in July, Kerendia added heart failure with left ventricular ejection fraction (LVEF) ≥ 40% to its US label. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Oelrich therefore said Bayer expects revenue losses reported in the first nine months of 2025 to stabilise in 2026 as the full impact of declining Xarelto sales are felt. After this, he said the company expects mid-single digit growth from 2027 to 2030. However, Oelrich recognised the limits of Bayer’s strategy against losses of exclusivity, saying, “on the next patent cliff it will probably not be possible to redo the same as we did this time, because we cannot re-enter the US twice”. He said the company is therefore looking to conclude more deals for early-stage and preclinical assets, though this requires Bayer to reduce its debts and improve its credit rating. “We expect to do more as we improve our own financial health … we expect to have more availability for deal-making,” Oelrich stated. Sign up here to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare Conference 2026. Sign up here to receive a comprehensive report after the conference.